Economic Burden of Hypoglycemia in Patients with Type 2 Diabetes Mellitus from Korea

PLoS One. 2016 Mar 14;11(3):e0151282. doi: 10.1371/journal.pone.0151282. eCollection 2016.

Abstract

Background: Hypoglycemia is a very serious complication in patients with type 2 diabetes mellitus (T2DM) and affects the economic burden of treatment. This study aims to create models of the cost of treating hypoglycemia in patients with T2DM based upon physician estimates of medical resource usage.

Methods: Using a literature review and personal advice from endocrinologists and emergency physicians, we developed several models for managing patients with hypoglycemia. The final model was approved by the consulting experts. We also developed 3 unique surveys to allow endocrinologists, emergency room (ER) physicians, and primary care physicians to evaluate the resource usage of patients with hypoglycemia. Medical costs were calculated by multiplying the estimated medical resource usage by the corresponding health insurance medical care costs reported in 2014.

Results: In total, 40 endocrinologists, 20 ER physicians, and 30 primary care physicians completed the survey. We identified 12 types of standard medical models for secondary or tertiary hospitals and 4 for primary care clinics based on the use of ER, general ward, or intensive care unit (ICU) and patients' status of consciousness and self-respiration. Estimated medical costs per person per hypoglycemic event ranged from $17.28 to $1,857.09 for secondary and tertiary hospitals. These costs were higher for patients who were unconscious and for those requiring ICU admission.

Conclusion: Hypoglycemia has a substantial impact on the medical costs and its prevention will result in economic benefits for T2DM patients and society.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cost of Illness*
  • Diabetes Mellitus, Type 2 / complications*
  • Diabetes Mellitus, Type 2 / economics*
  • Diabetes Mellitus, Type 2 / therapy
  • Health Care Costs
  • Humans
  • Hypoglycemia / complications*
  • Hypoglycemia / economics*
  • Hypoglycemia / therapy
  • Middle Aged
  • Primary Health Care / economics
  • Republic of Korea
  • Secondary Care Centers
  • Tertiary Care Centers / economics

Grants and funding

Funding for this study was provided by MSD Korea LTD, a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. The sponsor participated in part of study design, but had no role in data collection and analysis, decision to publish, or preparation of the manuscript. GK, Y-hL, E-KL, CHK, HSK, IKJ, ESK, DJK have no financial disclosures. MHH is employee of MSD Korea.